Histamine H3 Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Histamine H3 receptor neurons represent a critical component of the histaminergic system in the brain, expressing the H3 subtype of histamine receptors that function as presynaptic autoreceptors and heteroreceptors. These neurons play essential roles in regulating neurotransmitter release, wakefulness, cognition, and have emerged as important therapeutic targets in neurodegenerative and sleep disorders. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Receptor neurons | [4]
| Primary Receptor | H3 (encoded by HRH3 gene) | [5]
| Neurotransmitter | Histamine | [6]
| Signal Transduction | Gi/o protein-coupled inhibition of adenylate cyclase | [7]
| Brain Regions | Cortex, basal ganglia, hippocampus, hypothalamus, thalamus |
| Expression Pattern | Presynaptic terminals (autoreceptor), postsynaptic (heteroreceptor) |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
The HRH3 gene is located on chromosome 20q13.33 and encodes multiple splice variants:
| Isoform | Distribution | Function |
|---|---|---|
| H3R (441 aa) | Full-length, brain | Canonical signaling |
| H3R(365) | Truncated | Dominant-negative |
| H3R(394) | Alternative splicing | Tissue-specific |
| H3R(413) | Peripheral tissues | Modified pharmacology |
H3 receptors are Class A GPCRs with:
Upon histamine binding (or constitutive activity):
H3 receptors on histaminergic neurons function as autoreceptors:
H3 receptors modulate other neurotransmitter systems:
| Neurotransmitter | Effect | Brain Region |
|---|---|---|
| Acetylcholine | Inhibition | Cortex, hippocampus |
| Dopamine | Inhibition | Striatum, prefrontal cortex |
| GABA | Inhibition | Cortex, basal ganglia |
| Glutamate | Inhibition | Cortex |
| Norepinephrine | Inhibition | Locus coeruleus |
| Serotonin | Inhibition | Raphe nuclei |
Histaminergic neurons in the tuberomammillary nucleus (TMN) are critical for arousal:
H3 receptors are validated therapeutic targets:
| Drug | Approval | Indication | Dose |
|---|---|---|---|
| Pitolisant | 2016 (FDA) | Narcolepsy | 5-40 mg/day |
| Pitolisant | 2019 (FDA) | Obstructive sleep apnea | 5-40 mg/day |
H3 receptors are implicated in AD pathophysiology:
| Drug | Mechanism | Indication |
|---|---|---|
| Pitolisant | H3 inverse agonist | Narcolepsy, OSA |
| Compound | Company | Indication | Status |
|---|---|---|---|
| Bavenantron | Various | Schizophrenia | Phase II |
| GSK239512 | GSK | AD | Phase I/II |
| MK-6096 | Merck | ADHD | Phase II |
](/brain-regions/hrh3-gene
--histamine-h3-receptor-protein
--tuberomammillary-nucleus)## Background
The study of Histamine H3 Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schwartz JC. The histamine H3 receptor: From discovery to clinical trials with pitolisant. Br J Pharmacol. 2011 Jun;163(4):713-21. 2011. ↩︎
Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008 Jul;88(3):1183-241. 2008. ↩︎
Timm J, Marr I, Werfel SC, Engelhardt R, Ghorai PK, Kruse MS, et al. Molecular features determining ligand binding to the H3R binding pocket. Front Pharmacol. 2018 Feb;9:21. 2018. ↩︎
Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Dorr P, Yates R. The histamine H3 antagonist pitolisant: An overview of current clinical research. Sleep Med Rev. 2017 Aug;34:13-17. 2017. ↩︎
Brabant C, Alleva L, Grisar T, Chtarto A, Hanon O, Lamberty Y, et al. Effects of the H3 receptor agonist immepip and antagonist thioperamide on cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jan;33(1):120-30. 2009. ↩︎
Witkin JM, Nelson DL, Hyun J, Schwarz TK, Boggs JD, McClure LY, et al. Discovery of pitolisant, a histamine H3-receptor antagonist/inverse agonist for the treatment of narcolepsy. ACS Med Chem Lett. 2020 Feb;11(5):919-27. 2020. ↩︎
Baudrexel S, Müller K, Hilker R. Histamine and sleep: Pitolisant in narcolepsy and obstructive sleep apnea. Nervenarzt. 2021 Mar;92(3):259-67. German. 2021. ↩︎